CClinicalTrials.gg
Sign In
Status unknownNCT00785187Updated Nov 5, 2008

Affect of Dose Rate on UVR Induced Skin Erythema

An interventional study of exposure to UVB radiation in Erythema, sponsored by Goldenhersh, Michael, M.D.. Status unknown. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-11-05.

Sponsored by Goldenhersh, Michael, M.D. · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Nov 2008), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Purpose of study: Evaluation of the affect of dose rate on UVR induced skin erythema.

Study design: A single-center, prospective, randomized, crossover, open study.

Number of patients: 20-40

Patient population: Healthy volunteers

Control: Different sites on patients body

Procedure duration: Total 3-5 hours (4 visits)

Duration of follow up: 4 days

Duration of study: Up to 6 months

Primary objectives: To examine the difference in erythemal response as a function of dose rate, and to assess the total amount of energy that is theoretically transmitted through a sunscreen within the range of SPF 2-10.

02

Conditions studied

  • Erythema

Browse trials for

Keywords

  • UVB induced skin erythema
03

In context

Erythema

133 studies on the registry are indexed under Erythema; 11 are open to participants now.

This study's planned enrollment of 40 is below the median of 59 across 110 interventional studies indexed under Erythema.

Browse Erythema studies →

Lead sponsor

This is the only study on the registry with Goldenhersh, Michael, M.D. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Fitzpatrick Skin types I-III.
  • Age 18-60.
  • Absence of obvious sun damage on the volar side of the forearm or other exposure sites.
  • Absence of exposure of the arms or other exposure sites to sunlight for two weeks prior to the experiment.

Exclusion criteria

Exclusion Criteria:

  • History of skin cancer.
  • Multiple nevi or atypical nevi on the forearm.
  • Signs of sun damage on the volar side of the forearm or other exposure sites.
  • Mentally incompetent.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Interventions

  • Deviceexposure to UVB radiation

    exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.

06

What researchers measure

Primary outcomes

  1. To examine the difference in erythemal response as a function of dose rate, and to assess the total amount of energy that is theoretically transmitted through a sunscreen within the range of SPF 2-10

    Time frame: end of study

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 5, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00785187
Lead sponsor
Goldenhersh, Michael, M.D.
First posted
Nov 5, 2008
Start date
Dec 2008
Primary completion
Feb 2009 (estimated)
Last update
Nov 5, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Erythema→

Start the discussion